Clinicopathological features of patients with coexistence of secondary hyperparathyroidism and incidental papillary thyroid carcinoma

Yıl 2024, Cilt: 17 Sayı: 1 , 24 - 29 , 08.01.2024

Gökalp Okut , Murat Karataş , Ali Murat Yıldırım , Mehmet Alperen Uğur

https://izlik.org/JA42NT84FW

Öz

Objective: The clinicopathological features of Secondary hyperparathyroidism (SHPT)-associated papillary thyroid carcinoma (PTC) are unclear and further investigation is required. In this study, it was aimed to evaluate the rate of PTC and tumor characteristics in the results of thyroidectomy performed for non-tumor reasons in patients with SHPT.
Material and Methods: The data of 54 patients who underwent thyroidectomy with parathyroidectomy due to SHPT were analyzed. The patients were divided into two groups; patients with thyroid malignancy (group M) and patients without (group B).
Results: PTC was detected in 12 (22.2%) of 54 patients who underwent parathyroidectomy and thyroidectomy for SHPT. There was no difference between the groups in terms of gender (p=0.95), age (p=0.75), duration of hemodialysis (p=0.30). Preoperative mean parathormone level was higher in patients with malignancy (p=0.02). The thyroid nodule sizes of the patients in Group M were statistically significantly larger (17.8 ± 9.1 mm vs 13.09 ± 4.73 mm, p=0.02). Recurrence of PTC developed in the 19th month of the follow-up in one of our patients. The mean follow-up period of all patients was 22 ± 20.72 months.
Conclusion: In order not to overlook the association of PTC in patients with SHPT, surgeons should perform adequate preoperative examinations and be more careful during surgery

Anahtar Kelimeler

secondary hyperparathyroidism , papillary thyroid carcinoma , end stage renal disease

Kaynakça

• 1. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109.
• 2. Garabed E, Norbert L, Bertram LK. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney International Supplement. 2017;7(1):1–59.
• 3. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017;24(5):332.
• 4. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumeni Jr JF. Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol. 1987;126(3):370–376.
• 5. Kissin M, Bakst H. Co-existing myxedema and hyperparathyroidism: case report. J Clin Endocrinol. 1947;7(2):152–158.
• 6. Ma J, Mao Z, Yao Y, Lu Y, Wang H, Yang Y, et al. Coexistence of papillary thyroid carcinoma in secondary hyperparathyroidism. BMC Surg. 2021;21(1):1–6.
• 7. Group KDIGO (KDIGO) C-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1–130.
• 8. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
• 9. Cooper DS. American Thyroid Association (ATA) guidelines task force on thyroid nodules and differentiated thyroid cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. 10. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017;123(3):372–381. 11. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17(1):45–63.
• 12. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved. Am J Nephrol. 1998;18(2):89–95.
• 13. Lin S-Y, Lin W-M, Lin C-L, Yang T-Y, Sung F-C, Wang Y-H, et al. The relationship between secondary hyperparathyroidism and thyroid cancer in end-stage renal disease: a population-based cohort study. Eur J Intern Med. 2014;25(3):276–280. 14. Seehofer D, Rayes N, Klupp J, Nüssler NC, Ulrich F, Graef K-J, et al. Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature. World J Surg. 2005;29(9):1180–1184.
• 15. 2017 Yılı Türkiye Kanser İstatistikleri [Internet]. Available from: https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri
• 16. Burmeister LA, Sandberg M, Carty SE, Watson CG. Thyroid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer. 1997;79(8):1611–1616.
• 17. Kutlutürk K, Otan E, Yağcı MA, Usta S, Aydın C, Ünal B. Thyroid pathologies accompanying primary hyperparathyroidism: a high rate of papillary thyroid microcarcinoma. Turk J Surg. 2014;30(3):125.
• 18. Preda C, Branisteanu D, Armasu I, Danila R, Velicescu C, Ciobanu D, et al. Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. BMC Surg. 2019;19(1):1–10.
• 19. Masatsugu T, Yamashita H, Noguchi S, Nishii R, Watanabe S, Uchino S, et al. Significant clinical differences in primary hyperparathyroidism between patients with and those without concomitant thyroid disease. Surg Today. 2005;35(5):351–356.
• 20. Ieni A, Barresi V, Cardia R, Licata L, Di Bari F, Benvenga S, et al. The micropapillary/hobnail variant of papillary thyroid carcinoma: a review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord. 2016;17(4):521–527.
• 21. Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016;4(11):933–942.